
Replimune Group Inc
REPLHealthcare|Biotechnology|USA
$10.99
-0.12 (-1.08%)
Tangible Book
$2.01
Earnings Power
$1.15
Analyst Estimates
annual
{
"date": [
"202703",
"202803",
"202903",
"203003",
"203103"
],
"revenue_estimate": [
18.28,
112.54,
137.62,
230.94,
349.83
],
"ebit_estimate": [
-229.24,
-113.3,
-47.93,
1.65,
-36.2
],
"ebitda_estimate": [
null,
null,
null,
null,
null
],
"net_income_estimate": [
-222.34,
-148.03,
-45.4,
0.76,
-39.63
],
"per_share_eps_estimate": [
-1.97,
-0.91,
-0.54,
-0.03,
-0.36
],
"eps_nri_estimate": [
-2.21,
-1.19,
-0.54,
-0.03,
-0.36
],
"dividend_estimate": [
null,
1,
null,
null,
null
],
"book_value_per_share_estimate": [
null,
null,
null,
null,
null
],
"pretax_income_estimate": [
-176.32,
-148.03,
-76.46,
-45.96,
-39.63
],
"operating_cash_flow_per_share_estimate": [
null,
null,
null,
null,
null
],
"roa_estimate": [
null,
null,
null,
null,
null
],
"roe_estimate": [
null,
null,
null,
null,
null
],
"gross_margin_estimate": [
null,
null,
null,
null,
null
],
"operating_cash_flow_estimate": [
null,
null,
null,
null,
null
],
"pettm_estimate": [
0,
0,
0,
0,
0
],
"long_term_growth_rate_mean": 45.69,
"long_term_revenue_growth_rate_mean": "0.00",
"future_per_share_eps_estimate_growth": 46.51,
"future_eps_nri_estimate_growth": 45.69,
"future_revenue_estimate_growth": null,
"future_ebit_estimate_growth": 47.27,
"future_ebitda_estimate_growth": null,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": 46.25,
"future_pretax_income_estimate_growth": 35.71,
"future_book_value_per_share_estimate_growth": null,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": null,
"future_gross_margin_estimate_growth": null,
"future_operating_cash_flow_per_share_estimate_growth": null
}
quarterly
{
"date": [
"202606",
"202609",
"202612",
"202703",
"202706",
"202709",
"202712",
"202803"
],
"revenue_estimate": [
0.62,
1.32,
10.88,
13.77,
31.9,
35.9,
39.8,
43.3
],
"ebit_estimate": [
-59.85,
-58.77,
-50.97,
-50.51,
-65.43,
-66.08,
-66.74,
null
],
"ebitda_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"net_income_estimate": [
-59.58,
-58.59,
-50.88,
-50.4,
-65.95,
-66.65,
-67.37,
null
],
"per_share_eps_estimate": [
-0.6,
-0.59,
-0.51,
-0.48,
-0.33,
-0.31,
-0.29,
-0.27
],
"eps_nri_estimate": [
-0.6,
-0.59,
-0.53,
-0.51,
-0.41,
-0.4,
-0.39,
-0.34
],
"dividend_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"pretax_income_estimate": [
-58.18,
-57.71,
-49.82,
-150.77,
-65.95,
-66.65,
-67.37,
null
],
"operating_cash_flow_per_share_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"roa_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"roe_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"gross_margin_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"operating_cash_flow_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"pettm_estimate": [
0,
0,
0,
0,
0,
null,
null,
null
],
"long_term_growth_rate_mean": 45.69,
"long_term_revenue_growth_rate_mean": "0.00",
"future_per_share_eps_estimate_growth": 46.51,
"future_eps_nri_estimate_growth": 45.69,
"future_revenue_estimate_growth": null,
"future_ebit_estimate_growth": 47.27,
"future_ebitda_estimate_growth": null,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": 46.25,
"future_pretax_income_estimate_growth": 35.71,
"future_book_value_per_share_estimate_growth": null,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": null,
"future_gross_margin_estimate_growth": null,
"future_operating_cash_flow_per_share_estimate_growth": null
}